Evidence map›Paper›PMID 35012582›Full record

ArticleRadiation oncology (London, England)2022

Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer.

Wenjuan Chen, Siyi Xiu, Xingyun Xie, Huiming Guo, Yuanji Xu, Penggang Bai, Xiaoyi Xia

Open access · goldAbstract read
In one paragraph

Article in Radiation oncology (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Promising predictive molecular biomarkers for cervical cancer (Review).International journal of molecular medicine · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Wenjuan Chen *Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou, 350000, Fujian, China. chenwj92@126.com.ORCID http://orcid.org/0000-0002-9262-5600
Siyi Xiu *Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou, 350000, Fujian, China.
Xingyun XieDepartment of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou, 350000, Fujian, China.
Huiming GuoDepartment of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou, 350000, Fujian, China.
Yuanji XuDepartment of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou, 350000, Fujian, China.
Penggang BaiDepartment of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou, 350000, Fujian, China.
Xiaoyi XiaDepartment of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, No. 420 Fuma Road, Fuzhou, 350000, Fujian, China.
Fujian Medical University · CN

Funding

Fujian Provincial Clinical Research Center Radiotherapy and Immunotherapy 2020Y2012Natural Science Foundation of Fujian Province 2020J011122
6 · The paper itself

Abstract

objectiveTo investigate the prognostic relevance of specific measurement parameters such as tumor diameter, tumor volume, tumor volume reduction rate (TVRR), and changes in the squamous cell carcinoma antigen (SCC-Ag) level in patients with locally-advanced cervical cancer (LACC) undergoing concurrent radiotherapy and chemotherapy.

methodsThis was a retrospective study of 203 patients with stage IIA-IVA cervical squamous cell carcinoma who were newly diagnosed at our hospital between January 2011 and March 2015. Clinical data and pre-and post-treatment imaging information were collected and each parameter was calculated using 3DSlicer software. The pre/post-treatment tumor diameter (TD

resultsThe median follow-up was 69 months. The 5-year overall survival (OS) and disease progression-free survival (PFS) rates were 69.5% and 64.5%, respectively. On univariate analysis, TD

conclusionTD

Indexed as

AdultAgedAntigens, NeoplasmBiomarkers, TumorCarcinoma, Squamous CellCombined Modality TherapyFemaleHumansMiddle AgedNeoplasm StagingPrognosisRetrospective StudiesSerpinsSurvival RateTumor BurdenUterine Cervical NeoplasmsAntigens, NeoplasmBiomarkers, TumorSerpinssquamous cell carcinoma-related antigenCervical cancerSquamous cell carcinoma antigen (SCC-Ag)Tumor diameterTumor volumeTumor volume reduction rate

Identifiers

PMID35012582
PMCPMC8751300
OpenAlexW4206433374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.